Variations in insurance coverage for autologous bone marrow transplantation for breast cancer

Kenneth J. Krause, Charles M. Cutler, I. Steven Udvarhelyi, William Winkenwerder, John K. Erban, Katherine M. Templeton, John R. Wingard, Vikram Khanna, William P. Peters, Mark C. Rogers

Research output: Contribution to journalLetter

Abstract

To the Editor: In concluding that the current process for making decisions about coverage of high-dose chemotherapy for breast cancer is “arbitrary and capricious,” Drs. Peters and Rogers (Feb. 17 issue)1 assume that … only insurers have a financial interest in making determinations about coverage. At the commonly quoted price of $150,000 per course of treatment, however, treatment of the 533 women in their analysis represents an annual income of $20 million to their institution alone. Institutions, providers, and suppliers all benefit substantially from insurance coverage for this treatment. Though the authors indicate otherwise, publication of their article.

Original languageEnglish (US)
Pages (from-to)329-331
Number of pages3
JournalNew England Journal of Medicine
Volume331
Issue number5
DOIs
StatePublished - Aug 4 1994

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Variations in insurance coverage for autologous bone marrow transplantation for breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Krause, K. J., Cutler, C. M., Udvarhelyi, I. S., Winkenwerder, W., Erban, J. K., Templeton, K. M., Wingard, J. R., Khanna, V., Peters, W. P., & Rogers, M. C. (1994). Variations in insurance coverage for autologous bone marrow transplantation for breast cancer. New England Journal of Medicine, 331(5), 329-331. https://doi.org/10.1056/NEJM199408043310514